Last Updated: July 14, 2026

Litigation Details for Huawei Technologies, Co, Ltd v. Samsung Electronics Co, Ltd. (N.D. Cal. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Huawei Technologies, Co, Ltd v. Samsung Electronics Co, Ltd.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for Huawei Technologies, Co, Ltd v. Samsung Electronics Co, Ltd. (N.D. Cal. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-05-24 External link to document
2016-05-24 168 Order 166 patent”); 8,812,848; 8,644,239 (“the ’239 patent”); 8,885,587; 8,885,583; 8,639,246…27 ’246 patent”); 8,412,197 (“the ’197 patent”); 8,996,003; and 8,724,613 (“the ’613 patent”). …26 Huawei has asserted U.S. Patent Nos. 8,369,278 (“the ’278 patent”); 8,416,892; 8,483,166 (“the …Samsung has asserted U.S. Patent Nos. 8,228,827, 8,315,195 (“the ’195 patent”), RE44,105, …8,457,588 (“the ’588 patent”), 8,509,350, 9,113,419, 8,619,726 (“the ’726 patent”), 8,761,130 External link to document
2016-05-24 191 Writ Issued U.S. Patent Nos. 8,369,278; 8,416,892; 8,483,166; 8,812,848; 8,644,239; 8,885,587; 8,885,583; 8,639,246;…standard-essential patents (“SEPS”). In addition, Huawei alleged that Samsung infringes eleven of its patents: U.S.…alleged that Huawei infringes nine of its patents: U.S. Patent Nos. 8,228,827; 8,315,195; RE44,105; 8,…that they infringe the patents asserted against them and contend that the patents asserted against them…art exists that anticipates the patented claims or renders the patented claims obvious. Huawei has alleged External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Executive summary

Last updated: June 25, 2026

  • Case: Huawei Technologies Co., Ltd. v. Samsung Electronics Co., Ltd., No. 3:16-cv-02787 (E.D. Texas).
  • Core posture: Patent infringement dispute focused on wireless device communications and related technology.
  • Outcome: No complete litigation record details can be produced from the information provided in the prompt alone (no court documents, claims/patents-in-suit, asserted asserted counts, claim construction outcomes, jury verdict/dismissal status, or appellate history). Per operating constraints, a complete and accurate litigation summary and analysis cannot be delivered.

Litigation summary for Huawei v Samsung Electronics (3:16-cv-02787)

Answer (status and merits): Not provided in the prompt; cannot be summarized accurately without filings and dispositions (complaint, Dkt. events, Markman order, trial/jury verdict, post-trial motions, settlement or judgment, and any appeal).

What patents were asserted in Huawei v Samsung (3:16-cv-02787)?

Answer: Not provided in the prompt.

What claims and issues did Samsung dispute?

Answer: Not provided in the prompt.

What did the court decide at Markman (claim construction)?

Answer: Not provided in the prompt.

What was the final judgment or dismissal basis?

Answer: Not provided in the prompt.

Did the parties settle, and what was the settlement timing?

Answer: Not provided in the prompt.

How strong was Huawei’s patent estate in Huawei v Samsung (3:16-cv-02787)?

Answer: Not provided in the prompt (requires asserted patents, validity/claim construction outcomes, and infringement findings).

Were validity defenses (anticipation, obviousness) resolved at summary judgment?

Answer: Not provided in the prompt.

Were there Rule 12/early dismissals?

Answer: Not provided in the prompt.

Were there damages rulings, including design-around or apportionment?

Answer: Not provided in the prompt.

What patent litigation strategy did Samsung use in Huawei v Samsung (3:16-cv-02787)?

Answer: Not provided in the prompt.

What were Samsung’s infringement positions (noninfringement theories)?

Answer: Not provided in the prompt.

What were Samsung’s invalidity and enforceability positions?

Answer: Not provided in the prompt.

What is the procedural timeline for Huawei v Samsung (3:16-cv-02787)?

Answer: Not provided in the prompt.

Key docket milestones needed for analysis

Answer: Not provided in the prompt (cannot reconstruct dates, Dkt. numbers, or rulings from the case number alone here).

How does this case affect Samsung’s wireless IP risk and future exposure?

Answer: Not provided in the prompt because merits outcome, patents-in-suit, and surviving issues determine downstream risk.

Key takeaways

  • A litigation summary and analysis for Huawei Technologies Co., Ltd. v. Samsung Electronics Co., Ltd., 3:16-cv-02787 cannot be produced from the prompt alone.
  • No actionable details (asserted patents, rulings, verdict/judgment, or settlement terms) are included, so any narrative would be incomplete or inaccurate.

FAQs

  1. What patents were asserted by Huawei in 3:16-cv-02787?
  2. Did Samsung win summary judgment, lose at trial, or obtain a dismissal in 3:16-cv-02787?
  3. What were the court’s claim construction holdings (Markman) in 3:16-cv-02787?
  4. Was there an appeal from 3:16-cv-02787, and what issues were argued?
  5. What were the damages outcomes (injunction, reasonable royalty, or lost profits) in 3:16-cv-02787?

References

  1. (No sources were provided in the prompt.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.